These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 25734660)

  • 1. Promising management of pazopanib-induced liver toxicity.
    Vlenterie M; van Erp NP; van der Graaf WT
    Acta Oncol; 2015 Jul; 54(7):1064-6. PubMed ID: 25734660
    [No Abstract]   [Full Text] [Related]  

  • 2. The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study.
    Nakamura T; Matsumine A; Kawai A; Araki N; Goto T; Yonemoto T; Sugiura H; Nishida Y; Hiraga H; Honoki K; Yasuda T; Boku S; Sudo A; Ueda T
    Cancer; 2016 May; 122(9):1408-16. PubMed ID: 26970174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A remarkable response to pazopanib, despite recurrent liver toxicity, in a patient with a high grade endometrial stromal sarcoma, a case report.
    Verschoor AJ; Warmerdam FARM; Bosse T; Bovée JVMG; Gelderblom H
    BMC Cancer; 2018 Jan; 18(1):92. PubMed ID: 29357824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response to pazopanib in two pediatric patients with pretreated relapsing synovial sarcoma.
    Casanova M; Basso E; Magni C; Bergamaschi L; Chiaravalli S; Carta R; Tirtei E; Massimino M; Fagioli F; Ferrari A
    Tumori; 2017 Jan; 103(1):e1-e3. PubMed ID: 27647230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined treatment with pazopanib and vinflunine in patients with advanced urothelial carcinoma refractory after first-line therapy.
    Gerullis H; Eimer C; Ecke TH; Georgas E; Arndt C; Otto T
    Anticancer Drugs; 2013 Apr; 24(4):422-5. PubMed ID: 23407060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response of refractory Ewing sarcoma to pazopanib.
    Alcindor T
    Acta Oncol; 2015 Jul; 54(7):1063-4. PubMed ID: 25345493
    [No Abstract]   [Full Text] [Related]  

  • 7. A phase I study on the combination of neoadjuvant radiotherapy plus pazopanib in patients with locally advanced soft tissue sarcoma of the extremities.
    Haas RL; Gelderblom H; Sleijfer S; van Boven HH; Scholten A; Dewit L; Borst G; van der Hage J; Kerst JM; Nout RA; Hartgrink HH; de Pree I; Verhoef C; Steeghs N; van Coevorden F
    Acta Oncol; 2015; 54(8):1195-201. PubMed ID: 25920360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-dose administration of oral pazopanib for the treatment of recurrent angiosarcoma.
    Miura H; Shirai H
    Clin Exp Dermatol; 2015 Jul; 40(5):575-7. PubMed ID: 25753734
    [No Abstract]   [Full Text] [Related]  

  • 9. Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial.
    Necchi A; Mariani L; Zaffaroni N; Schwartz LH; Giannatempo P; Crippa F; Morosi C; Lanocita R; Sava T; Ortega C; Messina C; Sacco C; Pennati M; Daidone MG; Nicolai N; De Braud F; Gianni AM; Salvioni R
    Lancet Oncol; 2012 Aug; 13(8):810-6. PubMed ID: 22819172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An open-label extension study to evaluate safety and efficacy of pazopanib in patients with advanced renal cell carcinoma.
    Sternberg CN; Davis ID; Deen KC; Sigal E; Hawkins RE
    Oncology; 2014; 87(6):342-50. PubMed ID: 25227656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Uterine sarcoma with posterior reversible encephalopathy syndrome associated with pazopanib.
    Tatsumichi T; Tanaka H; Okazaki T; Takahashi K; Suzuki K; Kawakita K; Houchi H; Kuroda Y; Kosaka S
    J Clin Pharm Ther; 2021 Feb; 46(1):223-226. PubMed ID: 33044009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer.
    Monk BJ; Mas Lopez L; Zarba JJ; Oaknin A; Tarpin C; Termrungruanglert W; Alber JA; Ding J; Stutts MW; Pandite LN
    J Clin Oncol; 2010 Aug; 28(22):3562-9. PubMed ID: 20606083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of pneumothorax in advanced and/or metastatic soft tissue sarcoma patients during pazopanib treatment.
    Nakano K; Inagaki L; Tomomatsu J; Motoi N; Gokita T; Ae K; Tanizawa T; Shimoji T; Matsumoto S; Takahashi S
    Clin Oncol (R Coll Radiol); 2014 Jun; 26(6):357. PubMed ID: 24630810
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacokinetic drug evaluation of pazopanib for the treatment of uterine leiomyosarcomas.
    Ferrero S; Leone Roberti Maggiore U; Aiello N; Barra F; Ditto A; Bogani G; Raspagliesi F; Lorusso D
    Expert Opin Drug Metab Toxicol; 2017 Aug; 13(8):881-889. PubMed ID: 28678537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe pazopanib-induced hepatotoxicity: clinical and histologic course in two patients.
    Klempner SJ; Choueiri TK; Yee E; Doyle LA; Schuppan D; Atkins MB
    J Clin Oncol; 2012 Sep; 30(27):e264-8. PubMed ID: 22802316
    [No Abstract]   [Full Text] [Related]  

  • 16. Mechanisms Underlying Vascular Endothelial Growth Factor Receptor Inhibition-Induced Hypertension: The HYPAZ Trial.
    Mäki-Petäjä KM; McGeoch A; Yang LL; Hubsch A; McEniery CM; Meyer PAR; Mir F; Gajendragadkar P; Ramenatte N; Anandappa G; Santos Franco S; Bond SJ; Schönlieb CB; Boink Y; Brune C; Wilkinson IB; Jodrell DI; Cheriyan J
    Hypertension; 2021 May; 77(5):1591-1599. PubMed ID: 33775123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bronchopleural fistula arising after commencement of pazopanib for progressive sarcoma.
    Cohen L; Neuhaus S; Chryssidis S; Kotasek D
    ANZ J Surg; 2017 Jul; 87(7-8):E48-E49. PubMed ID: 25556827
    [No Abstract]   [Full Text] [Related]  

  • 18. Phase I dose-finding study of pazopanib in hepatocellular carcinoma: evaluation of early efficacy, pharmacokinetics, and pharmacodynamics.
    Yau T; Chen PJ; Chan P; Curtis CM; Murphy PS; Suttle AB; Gauvin J; Hodge JP; Dar MM; Poon RT
    Clin Cancer Res; 2011 Nov; 17(21):6914-23. PubMed ID: 21831954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified Cooperstown 5+1 cocktail in patients with advanced solid tumors.
    Goh BC; Reddy NJ; Dandamudi UB; Laubscher KH; Peckham T; Hodge JP; Suttle AB; Arumugham T; Xu Y; Xu CF; Lager J; Dar MM; Lewis LD
    Clin Pharmacol Ther; 2010 Nov; 88(5):652-9. PubMed ID: 20881954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pazopanib in relapsed osteosarcoma patients: report on 15 cases.
    Longhi A; Paioli A; Palmerini E; Cesari M; Abate ME; Setola E; Spinnato P; Donati D; Hompland I; Boye K
    Acta Oncol; 2019 Jan; 58(1):124-128. PubMed ID: 30207179
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.